The next meeting of the Transparency Council will be held on June 13 (Monday).
AOTMiT: The Transparency Council will evaluate drugs, incl. for immune thrombocytopenia and squamous cell carcinoma of the head and neck
Published June 8, 2022 09:35
Źródło: AOTMiT
The agenda is:
Preparation of an opinion on the assessment of the validity of introducing a new division into limit groups in the area of reimbursed specialist prescription dressings used in chronic wounds and blistering epidermal detachment.
Preparation of a position on the evaluation of Nplate (romiplostimum) under the drug program: "Treatment of adults with immune thrombocytopenia (ICD-10 D69.3)".
Preparation of a position on the legitimacy of granting consent for the reimbursement of MSUD Anamix Infant foods for particular nutritional uses; MSUD Anamix Junior; MSUD Anamix Junior LQ; MSUD Gel; MSUD Cooler; MSUD Express; MSUD Lophlex LQ in the indications: maple syrup disease; beta-ketothiolase deficiency; 3-hydroxybutryl-CoA hydrolase deficiency.
Preparation of an opinion on changes to drug programs:
• 110 "Treatment with dinutuximab beta in patients with sympathetic neuroblastoma (ICD-10 C47)",
• 107 "Treatment of chronic spontaneous urticaria (ICD-10: L50.1)",
• “Treatment of patients with squamous cell carcinoma of the head and neck of the TPEx regimen with cetuximab in the first line of treatment of recurrent or metastatic squamous cell carcinoma of the head and neck organs”.
Preparation of an opinion on the draft health policy program of a local government unit: "Health policy program for seniors from the Kcynia commune for the years 2022-2025" Envelope of life - take care of your safety ".
Source: AOTMiT
